Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/32364
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBarrachina, Jordi-
dc.contributor.authorMargarit, César-
dc.contributor.authorMuriel, Javier-
dc.contributor.authorLópez‑Gil, Santiago-
dc.contributor.authorLópez Gil, Vicente-
dc.contributor.authorVara-González, Amaya-
dc.contributor.authorPlanelles, Beatriz-
dc.contributor.authorInda, María del Mar-
dc.contributor.authorMorales, Domingo-
dc.contributor.authorPeiró, Ana-
dc.contributor.otherDepartamentos de la UMH::Farmacología, Pediatría y Química Orgánicaes_ES
dc.date.accessioned2024-06-27T11:35:56Z-
dc.date.available2024-06-27T11:35:56Z-
dc.date.created2022-06-
dc.identifier.citationScientifics Reports . 2022 Jun 16;12(1):10126.es_ES
dc.identifier.issn2045-2322-
dc.identifier.urihttps://hdl.handle.net/11000/32364-
dc.description.abstractTapentadol (TAP) and oxycodone/naloxone (OXN) potentially offer an improved opioid tolerability. However, real-world studies in chronic non-cancer pain (CNCP) remain scarce. Our aim was to compare effectiveness and security in daily pain practice, together with the influence of pharmacogenetic markers. An observational study was developed with ambulatory test cases under TAP (n = 194) or OXN (n = 175) prescription with controls (prescribed with other opioids (control), n = 216) CNCP patients. Pain intensity and relief, quality of life, morphine equivalent daily doses (MEDD), concomitant analgesic drugs, adverse events (AEs), hospital frequentation and genetic variants of OPRM1 (rs1799971, A118G) and COMT (rs4680, G472A) genes, were analysed. Test CNCP cases evidenced a significantly higher pain relief predictable due to pain intensity and quality of life (R2 = 0.3), in front of controls. Here, OXN achieved the greatest pain relief under a 28% higher MEDD, 8-13% higher use of pregabalin and duloxetine, and 23% more prescription change due to pain, compared to TAP. Whilst, TAP yielded a better tolerability due the lower number of 4 [0-6] AEs/patient, in front of OXN. Furthermore, OXN COMT-AA homozygotes evidenced higher rates of erythema and vomiting, especially in females. CNCP real-world patients achieved higher pain relief than other traditional opioids with a better tolerability for TAP. Further research is necessary to clarify the potential influence of COMT and sex on OXN side-effects.es_ES
dc.formatapplication/pdfes_ES
dc.format.extent12es_ES
dc.language.isoenges_ES
dc.publisherNature Portfolioes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectGeneticses_ES
dc.subjectNeurosciencees_ES
dc.subjectMedical researches_ES
dc.subjectBiomarkerses_ES
dc.subjectPredictive markerses_ES
dc.subjectPrognostic markerses_ES
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicina::615 - Farmacología. Terapéutica. Toxicología. Radiologíaes_ES
dc.titleOxycodone/naloxone versus tapentadol in real-world chronic non-cancer pain management: an observational and pharmacogenetic studyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1038/s41598-022-13085-5es_ES
Appears in Collections:
Artículos Farmacología, Pediatría y Química Orgánica


Thumbnail

View/Open:
 Oxycodonenaloxone - naloxone versus tapentadol in real-world chronic non-cancer pain management.an observational and pharmacogenetic study.pdf

1,61 MB
Adobe PDF
Share:


Creative Commons ???jsp.display-item.text9???